Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-Intensity Conditioning with Fludarabine, Busulfan, and Alemtuzumab for Allo-HSCT
NCT00579111Phase 2Terminated
- Sponsor
- Baylor College of Medicine
- Start
- Jun 2007
- Primary completion
- Feb 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), sponsored by Baylor College of Medicine. Started Jun 2007; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
myelodysplastic syndrome (MDS)myeloproliferative neoplasms (MPN)acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00579111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00579111.